About CardioPolymers
CardioPolymers is a Healthcare company based in Laguna Hills (United States) founded in 2003, and was acquired by LoneStar Heart in June 2010. It operates as a biopolymer implant therapies are developed to treat cardiac abnormalities. CardioPolymers has raised $13.57 million across 1 funding round from investors including LoneStar Heart. The company was acqui-hired. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is CARDIOPOLYMERS, INC. Its competitors include Sequana Medical, CVRx, HeartWare, Element Science and Ancora Heart and 5 more; 10 of its 10 listed competitors have raised funding.
Company details
CardioPolymers was established in 2003 in Laguna Hills, United States, within the biomedical sector. Focus is placed on biopolymer-based implant therapies for addressing cardiac conditions, including dilated cardiomyopathy. Operations center on the development of Algisyl-LVR, an implantable device designed to halt or reverse congestive heart failure progression. Previously known as Symphony Medical, the company was acquired by LoneStar Heart in June 2010.
- Headquarters Laguna Hills, United States
- SectorsHealthcare
- Website cardiopolymers.com
- Social LinkedIn
- Acquired by LoneStar Heart (Jun 2010)
- Legal Name Cardiopolymers, Inc.
- Total Equity Funding$13.57M (USD)
in 1 rounds
- Latest Funding Round$13.57M (USD), Series B
Jul 2020
- Investors
- Acquired byLoneStar Heart
(Jun 2010)
Funding Insights of CardioPolymers
CardioPolymers has successfully raised a total of $13.57M through 1 strategic funding round. The most recent funding activity was a Series B round of $13.57 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.57M
- Total Rounds 1
- Last Round Series B — $13.57M
- First Round $13.57M
(Jul 2020)
All 1 funding rounds of CardioPolymers with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $13.57M | Series B | – | – | – |
1 investors in total: 1 institutional.
Investors in CardioPolymers
CardioPolymers has secured backing from 1 investor. Prominent investors backing the company include LoneStar Heart.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Develops cardiac therapies for patients with chronic heart failure. | 2010 | lonestarheartinc.com | Laguna Hills, United States |
Investor details for CardioPolymers
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of CardioPolymers
3 dated milestones of CardioPolymers across 17 years, from founding to its latest funding, stage changes and deals.
- Founded CardioPolymers is founded.
- Exit Acquired by LoneStar Heart.
- Funding First funding round of $13.6M.
Competitors of CardioPolymers
CardioPolymers has 10 listed competitors in our database, 10 of them funded. They include Sequana Medical, CVRx, HeartWare, Element Science and Ancora Heart, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sequanamedical.com | 2006 | Zurich, Switzerland | $35.5M | – | Implantable battery-powered pumps for ascites removal are developed. | |
| cvrx.com | 2001 | Minneapolis, United States | $368.5M | 142 | Implantable technology for hypertension and heart failure is developed. | |
| heartware.com | 2005 | Framingham, United States | $12.38M | 547 | Miniaturized ventricular assist devices are developed for heart failure treatment. | |
| elementscience.com | 2013 | San Francisco, United States | $192.6M | – | Wearable patch defibrillators are developed for sudden cardiac arrest treatment. | |
| ancoraheart.com | 2001 | San Francisco, United States | $151.26M | 89 | Minimally invasive ventriculoplasty system for heart failure and FMR | |
| syncardia.com | 2001 | Tucson, United States | $60.96M | – | Total artificial hearts are developed for cardiac replacement therapy. | |
| adonamed.com | 2017 | Campbell, United States | $71M | – | Medical devices for heart failure management are developed. | |
| respicardia.com | 2006 | Minnetonka, United States | $184.62M | 68 | Manufacturing implantable stimulation device to improve cardiovascular health by restoring natural breathing at night | |
| bioventrix.com | 2003 | San Ramon, United States | $181.42M | 20 | Ventricular reconstruction devices for heart failure are developed. | |
| alleviantmedical.com | 2017 | Houston, United States | $179.87M | – | Developer of devices to lift the burden of heart failure |
Detailed competitors of CardioPolymers
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
10 companies that operate in the same segment as CardioPolymers (Cardiac and Vascular Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Connected devices for health, sleep, and activity monitoring are developed. | 2008 | Moulineaux, Seine-maritime, France | USD 93.83 M | – | – | |
SMT is recognized as a developer of cardiovascular medical devices. | 1998 | Surat, Gujarat, India | USD 57.22 M | USD 106.25 M | 1,090 | |
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | – | 255 | |
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 | |
Cloud-based ambulatory ECG monitors for cardiac arrhythmia diagnosis are provided. | 2006 | San Francisco, California, United States | USD 109.23 M | USD 747.14 M | 2,000 | |
Provider of neuroprotection devices for carotid artery disease | 2007 | Sunnyvale, California, United States | USD 241.8 M | – | – | |
Miniaturized wireless implantable sensors are developed for hemodynamic monitoring. | 2007 | East Peoria, Illinois, United States | USD 154.77 M | – | 104 | |
Access catheters for neurovascular stroke treatment are provided. | 2015 | Campbell, California, United States | USD 596 M | – | – | |
Biosensor patches are developed for monitoring multiple body vitals. | 2011 | Campbell, California, United States | USD 239.95 M | – | 184 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CardioPolymers
CardioPolymers was founded in 2003 and raised its 1st funding round 17 years after it was founded.
CardioPolymers is headquartered in Laguna Hills, United States. It is registered at Laguna Hills, California, United States.
CardioPolymers is a funded company, having raised a total of $13.57M across 1 funding round to date. The company's 1st funding round was a Series B of $13.57M, raised on Jul 2020.
CardioPolymers was established in 2003 in Laguna Hills, United States, within the biomedical sector. Focus is placed on biopolymer-based implant therapies for addressing cardiac conditions, including dilated cardiomyopathy. Operations center on the development of Algisyl-LVR, an implantable device designed to halt or reverse congestive heart failure progression. Previously known as Symphony Medical, the company was acquired by LoneStar Heart in June 2010.
CardioPolymers's top competitors include Sequana Medical, CVRx and Adona Medical.
CardioPolymers has 1 investor. Key investors include LoneStar Heart.
CardioPolymers operates through Cardiopolymers, Inc..
Yes. CardioPolymers was acquired by LoneStar Heart in June 2010.